Young J H, Currie W J
Curr Med Res Opin. 1983;8 Suppl 2:99-108. doi: 10.1185/03007998309109829.
'Osmosin' (105 mg sodium indomethacin trihydrate) has been studied in a double-blind general practice trial of patients with osteoarthritis of the hip at a dose of 1 tablet in the morning and matching placebo at night versus 1 tablet twice daily. To date, 223 patients have completed the study, 113 in the lower dose and 110 in the higher dose group. In the preliminary analysis, the overall trend at 4 weeks favoured the higher dose in effectiveness and this group appeared to respond more rapidly. The incidence of side-effects was similar in both groups, but there were fewer drop-outs due to side-effects in the group receiving 'Osmosin' once daily. The preliminary results indicate that the response to 'Osmosin' is time-dependent as well as dose-dependent and, therefore, rather than increasing the dose early, it is probably preferable to initiate therapy with 1 'Osmosin' daily and review at 1 month the need to increase the dose to 1 'Osmosin' twice daily.
“奥索辛”（105毫克三水合吲哚美辛钠）已在一项针对髋关节骨关节炎患者的双盲全科医疗试验中进行了研究，给药剂量为早上1片，晚上服用匹配的安慰剂，与每日两次各服用1片进行对比。迄今为止，223名患者已完成该研究，低剂量组113人，高剂量组110人。在初步分析中，4周时的总体趋势显示高剂量在疗效上更具优势，且该组似乎反应更快。两组的副作用发生率相似，但每日服用一次“奥索辛”的组因副作用导致的退出人数较少。初步结果表明，对“奥索辛”的反应既与时间有关，也与剂量有关，因此，与其早期增加剂量，可能更可取的做法是开始时每日服用1片“奥索辛”，并在1个月时评估是否需要将剂量增加至每日两次各服用1片。
